Skip to content

DENTSPLY SIRONA XRAY Stock-Based Comp

Stock-Based Comp at other companies

Align Technology logo
Align TechnologyALGN
$40.92M-9.1%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$10.2M+43.7%
Solventum logo
SolventumSOLV
$51M+4.1%
IAR
Integra LifeSciencesIART
$5.17M+176%
Henry Schein logo
Henry ScheinHSIC
$3M-40.0%
Globus Medical logo
Globus MedicalGMED
$12.62M-4.5%

Other financials

Income statement

See full
Revenue$880.0M+0.1%
Gross profit$427.0M-8.4%
Operating income-$35.0M-156%
Net income-$10.0M-150%
EPS (diluted)-$0.05-150%

Balance sheet

See full
Cash & equivalents$190.0M-52.3%
Total debt$2.3B-3.8%
Total equity$1.3B-34.4%
Total assets$5.2B-13.6%

Cash flow

See full
Operating cash flow$40.0M+471%
CapEx$52.0M+174%
Free cash flow-$12.0M0.0%

Valuation

See full
Market cap$2.11B-22.1%

Profitability

See full
Gross margin48.9%-2.6pp
Operating margin-14.1%-3.9pp
Net margin-17.1%-3.9pp
FCF margin2.8%-4.6pp

Returns & leverage

See full
Return on equity-37.7%+4.0pp
Debt / equity1.8×+0.6×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by DENTSPLY SIRONA in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: DENTSPLY SIRONA’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about DENTSPLY SIRONA's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DENTSPLY SIRONA's stock-based comp?
DENTSPLY SIRONA (XRAY) reported stock-based comp of $8M in Q1 2026.
How has DENTSPLY SIRONA's stock-based comp changed year-over-year?
DENTSPLY SIRONA's stock-based comp decreased by 20.0% year-over-year, from $10M to $8M.
What is the long-term trend for DENTSPLY SIRONA's stock-based comp?
Over 3 years (2022 to 2025), DENTSPLY SIRONA's stock-based comp has grown at a -17.6% compound annual growth rate (CAGR), from $59M to $33M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.